Benzinga | Aug 17, 2020 06:54AM EDT

Lannett Signs Agreement To Be Exclusive Distributor Of Generic Flovent Diskus, Lannett Extends its Exclusive Distribution Agreement with Respirent for Generic ADVAIR DISKUS From 10 to 12 Years

Lannett Company, Inc. (NYSE:LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent(r) Diskus(r) (Fluticasone Propionate Powder Inhaler) of Respirent Pharmaceuticals Co. Ltd. According to the Orange Book, all patents covering Flovent Diskus have expired. U.S. sales of Flovent Diskus, which have been increasing in recent years, were $94 million for the 12 months ending June, 2020 according to IQVIA, although actual generic market values are expected to be lower.